According to the results of a study conducted by experts from University Medical Center of Texas in Galveston, United States ( University of Texas Medical Branch ), half of women using injectables suffers loss of bone mineral density in the hip or the bottom of column two years after starting treatment.
The article, published in the January 2010 issue of the journal Obstetrics and Gynecology , main objective is to identify factors predictive of increased bone loss, defined as at least 5% at the spine or femoral neck loa medrosiprogesterona users acetate (DMPA) over time.
research to patients was measured bone mineral density (BMD) every six months in the lumbar spine and femoral neck. The initial sample consisted of 240 white women, black and Hispanic.
De
these two hundred and forty patients, ninety-five completed the twenty-four month period. As a result it was found that forty-five of them (more than half ) had a loss of at least five percent of bone mineral density, and a total of fifty women suffered a smaller percentage for the same time.
Another interesting for the experts was the observation in those female smokers who had not yet been mothers or whose daily calcium intake was less than 600 milligrams . The risk of loss of density bone mineral was greater for these women.
Despite all this the author of the study, Dr. Abbey Berenson (in Figure 2) he emphasized that the loss of bone mineral density should not be a major concern for all women who choose DMPA as a contraceptive treatment. Mahrburbur Professor Rahman, another of the center's researchers, said in turn that the recovery of this loss takes time, especially in women using this contraceptive.
SOURCES: EUROPA PRESS, Obstetrics & Gynecology.
0 comments:
Post a Comment